Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00711100 · ClinicalTrials.gov registry record · NA
Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers
A NA study of Tobacco Use Disorder, sponsored by University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 104
- Enrollment target
- 2
- Study locations
NCT00711100 is a NA study of Tobacco Use Disorder that has completed, run by University of Minnesota. The registered enrollment target is 104 participants, below the 238-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (56% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00711100, a NA study of Tobacco Use Disorder, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 104 participants
- Enrollment target
- 2
- Study locations
Study Summary
Recently, tobacco companies have developed new oral tobacco products that are purportedly less harmful than conventional tobacco products. These products have not been tested by independent research for their health effects or consumer palatability. In addition, it is not known if these products will be used in addition to cigarette smoking or as a substitute to cigarettes. These two studies will examine four oral tobacco products to answer some of these questions. The goals of this first study will be to examine: 1) the brand of oral tobacco products which is preferred by cigarette smokers and the pattern and amount of product use when used as a switching tool; 2) the characteristics that are associated with product choice; 3) nicotine exposure from these products; and 4) the withdrawal symptoms from the tobacco products and potential for continued use. Specifically, our primary aims hypotheses were: 1) the product that will be chosen by most smokers will be based on taste and sensory aspects of the product with products higher in nicotine content more likely to be chosen as the preferred product; and 2) subjects will experience no difficulty using the product for complete cigarette substitution, but a small minority will engage in dual product use. For the secondary aims, we hypothesized: 1) that compared to the subjects' own brand of cigarettes, the biomarkers for exposure for the oral tobacco products will be significantly lower; 2) withdrawal symptoms from the oral products are likely to occur, but are likely to be mild compared to cigarette withdrawal.
Conditions Studied
Interventions
- OTHER Camel Snus
- OTHER Marlboro Snus
- OTHER Stonewall
- OTHER Ariva
- OTHER General Snus
Study Locations (2)
Minnesota
- Univeristy of Minnesota - Minneapolis
Oregon
- Oregon Research Institute - Eugene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2008-08 |
| Est. Completion | 2010-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00711100
The ClinicalTrials.gov registry entry for NCT00711100 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 238-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (56% lower). The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tobacco Use Disorder appearing as the primary indexed condition, and to 5 interventions - of which Camel Snus is the first listed.
NCT00711100 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Minnesota, Oregon.
Frequently Asked Questions
What is clinical trial NCT00711100 about?
NCT00711100 is a clinical study titled "Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers". Recently, tobacco companies have developed new oral tobacco products that are purportedly less harmful than conventional tobacco products. These products have not been tested by independent research for their health effects or consumer palatability. In addition, it is not known if these products wil...
What is the current status of trial NCT00711100?
This trial is currently completed. It is a NA study. The enrollment target is 104 participants. The study started on 2008-08. Estimated completion is 2010-12.
What conditions does trial NCT00711100 study?
This clinical trial studies the following conditions: Tobacco Use Disorder.
What interventions are being tested in trial NCT00711100?
The interventions under investigation include: Camel Snus (OTHER), Marlboro Snus (OTHER), Stonewall (OTHER), Ariva (OTHER), General Snus (OTHER).
Who is sponsoring clinical trial NCT00711100?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00711100 being conducted?
This trial has 2 study locations across Minnesota, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Smoking Cessation CM for Veterans With or at Risk for Cancer
RECRUITING · NA
-
Smoking Cessation Behavioral Treatment Study
RECRUITING · NA
-
Contingency Management for Veteran Smokers Undergoing Major Elective Surgery
RECRUITING · NA
-
A Future Thinking Intervention for Comorbid Tobacco Use Disorder and Bipolar Disorder
RECRUITING · NA
-
Young Adult Tobacco/Nicotine and Cannabis Co-use
RECRUITING · NA
-
Low Intensity Focused Ultrasound for Tobacco Use Disorder: High Resolution Targeting of the Human Insula
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.